Royal Society of Chemistry | Books | rsc.li/medicinal-books
Royal Society of Chemistry | Books | rsc.li/medicinal-books
Drug Discovery
Drug Discovery
Chemical Linkers in Antibody-Drug Conjugates (ADCs) Floris van Delft Synaffix BV, Netherlands | John M. Lambert Immunogen Inc., USA Chemical Linkers in Antibody-Drug Conjugates aims to shine a detailed light on the various key attributes of chemical linkers in ADCs, for drug-to-antibody ratio, for stability, for release mechanism of payload, for pharmacokinetics, for stability determination, and for efficacy and safety. Ideal for postgraduate students and active researchers in drug discovery and development, this book provides a comprehensive description of linkers used in ADCs (clinical and late preclinical), insight into key quality attributes of linkers for ADCs, and aids the reader in understanding the role of linker chemistry and designing new ADCs.
Hardback | 300 pages 9781839162633 | 2022 £169.00 | $250.00
About the series ISSN 2041-3203 Editor-in-chief David E. Thurston King's College London, UK Series editors David Fox Vulpine Science & Learning, UK | Ian Storer AstraZeneca, UK | Corey Hopkins Vanderbilt University, USA The Drug Discovery Series covers all aspects of drug discovery and medicinal chemistry and contains over 70 books published since 2010. Providing comprehensive coverage of this important and far-reaching area, the books encourage learning in a range of different topics and provide valuable reference sources for scientists working outside their own areas of expertise. Books feature case studies to bring different aspects of the drug discovery process alive and they detail the fundamental science necessary for understanding through to the most up-to-date discoveries and cutting-edge technologies. Chapters are written and edited by experienced researchers from both industry and academia. This series will be of particular interest to postgraduate students and medicinal chemists and biochemists working in academia or industry. Antiviral Discovery for Highly Pathogenic Emerging Viruses César Muñoz-Fontela Bernhard Nocht Institute for Tropical Medicine, Germany | Rafael Delgado Hospital Universitario 12 de Octubre, Spain New antivirals are urgently needed. Recent outbreaks caused by viruses with great epidemiological impact such as Zika, or extraordinary virulence such as Ebola, Nipah, Lassa and Crimean-Congo haemorrhagic fever highlight the current lack of clinically proven vaccines and treatments for these potentially catastrophic agents. Antiviral Discovery for Highly Pathogenic Emerging Viruses will comprehensively outline the state of the art in antiviral drug discovery including identification of targets, screening, strategies, and the current pipeline of candidate antivirals. The book will also address the challenges faced in proceeding from pre-clinical studies to animal models and clinical trials with these highly pathogenic agents.
ee
Drug Repurposing David Cavalla Numedicus, UK
Hardback | 400 pages 9781788019033 | 2022 £179.00 | $250.00
ee
Drug Repurposing is the development of existing drugs for new uses: given that 9 in 10 drugs that enter drug development are never marketed and therefore represent wasted effort, it is an attractive as well as inherently more efficient process. Three repurposed drugs can be brought to market for the same cost as one new chemical entity; and they can also be identified more quickly, an important benefit for patients whose diseases are progressing faster than therapeutic innovation. This book provides a single source, comprehensive reference on the latest developments and innovations in drug repurposing ideal for students and researchers in pharmaceutical science and drug discovery. DNA-encoded Library Technology for Drug Discovery Jin Li HitGen Ltd., China | Barry Morgan HitGen Ltd., China | Casey J Krusemark Purdue University, USA DNA-Encoded libraries have numerous advantages over traditional screening methods including easy identification of compounds and the large quantity of compounds that can be screened simultaneously. This book provides a comprehensive guide to the implementation of DNA-Encoded Libary Technology (DELT) in drug discovery from encoding and library synthesis to screening and hit validation. A valuable resource for researchers in drug discovery, this book is complete with successful case studies to illustrate the best practice in implementation and operation of DELT.
Hardback | 312 pages 9781788015646 | 2022 £159.00 | $220.00
ee
Hardback | 350 pages 9781788014878 | 2022 £179.00 | $250.00
ee
54
55
Made with FlippingBook - Online magazine maker